The role of ivabradine in doxorubicin-induced cardiotoxicity: exploring of underlying argument

Hayder M. Al-kuraishy1 · Hajer K. Issa1 · Ali I. Al-Gareeb1 · Maisra M. El-Bouseary2 · Amal Youssef3 · Ahmed Shaban Abdelaziz4 · Hesham Ahmed Khalifa4 · Gaber El-Saber Batiha5

Received: 6 August 2022 / Accepted: 19 September 2022 / Published online: 11 October 2022
© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022

Abstract
This study investigated the potential role of ivabradine (IVN) in the attenuation of doxorubicin (DXR)-induced cardiotoxicity in rats. A total of 28 Swiss-Albino male mice were used, divided into four equal groups: the negative control did not receive any agents (n = 7), the DXR group received a single dose of DXR 20 mg/kg (n = 7), the treated group A was pretreated with IVN 5 mg/kg plus DXR (n = 7), and the treated group B was pretreated with IVN 10 mg/kg plus DXR (n = 7). The duration of this study was 10 days. Inflammatory biomarkers, including tumor necrosis factor alpha (TNF-α), lactate dehydrogenase (LDH), malondialdehyde (MDA), and cardiac troponin (cTn-I) serum levels were measured. TNF-α, LDH, MDA, and cTn-I serum levels were higher in the DXR-treated mice compared with the control (P < 0.01). IVN produced a dose-dependent effect in the reduction of MDA and cTn-I compared to DXR-treated mice (P < 0.05). Our findings suggest that IVN is an effective agent in mitigating DXR-induced cardiotoxicity due to its anti-inflammatory and antioxidant effects. IVN illustrated a dose-dependent effect in the attenuation of DXR-induced cardiotoxicity through inhibition of lipid peroxidation and cardiomyocyte injury.

Keywords Doxorubicin · Cardiotoxicity · Ivabradine · Lipid peroxidation · Cardiomyocyte injury

Introduction
Doxorubicin (DXR) is a cytotoxic drug belonging to the anthracycline antibiotic class used in the treatment of various malignancies, including leukemia, lymphoma, breast, and ovarian cancers (Jasim et al. 2019). DXR is a hydroxylated form of daunorubicin, which is abundant as a natural product of many strains of Streptomyces. In contrast, only Streptomyces cesius can produce DXR, thus other Streptomyces strains need to be genetically modified to produce DXR (Al-Kuraishy and Al-Gareeb 2016). In 1996, a gene encoding the conversion of daunorubicin to DXR was discovered (Al-Kuraishy and Al-Gareeb 2016). Acute or prolonged use of DXR is associated with different complications, including...
cardiotoxicity, nephrotoxicity, immunosuppression, bone marrow depression, and gastrointestinal disorders. DXR-induced cardiotoxicity is the most common complication linked with the use of DXR (Al-Kuraishy et al. 2015, 2021a).

DXR-induced cardiotoxicity is thought to be mediated by mechanisms, including reactive oxygen species (ROS) generation, lipid peroxidation, endoplasmic stress, mitochondrial dysfunction, and membrane integrity alteration (Sindhu et al. 2021; Al-Kuraishy et al. 2019, 2022a, b). DXR-induced cardiotoxicity is presented in diverse clinical forms, such as hypotension, arrhythmia, and acute heart failure (Kumari et al. 2020). Chronic use of DXR may lead to the development of congestive heart failure due to the propagation of dilated cardiomyopathy (Xu et al. 2020). Epidemiological and clinical trial studies indicate that DXR causes dose-dependent irreversible cardiotoxicity (Xu et al. 2020). In this state, various therapeutic strategies have been applied to attenuate the development of DXR-induced cardiotoxicity using antioxidants, β-adrenoceptor blockers, and renin–angiotensin system modulators (Lan et al. 2020). However, some of these cardio-protectant agents may interfere with the anticancer effect of DXR. Notably, phosphodiesterase 5 inhibitors, such as tadalafil and sildenafil, can reduce DXR-induced cardiotoxicity without interfering its anticancer effect (Koka et al. 2010; Shah et al. 2021).

Ivabradine (IVN) is an inhibitor of funny current (I f ) channels in the sinoatrial nodal tissue, which decreases heart rate, and it is used mainly in the management of sinus tachycardia. Unlike β-adrenoceptor blockers, IVN does not reduce the force of ventricular contraction, so it is safe to use in heart failure (Su et al. 2020). Of interest, a clinical trial revealed the effectiveness of IVN in decreasing the severity of heart failure and acute coronary syndrome through its anti-inflammatory and antioxidant properties (Su et al. 2020). Thus, the objective of the present study was to investigate the potential role of IVN in the attenuation of DXR-induced cardiotoxicity in rats.

Materials and methods

This study was performed in the College of Medicine, Department of Clinical Pharmacology and Therapeutic, Al-Mustansiriya University, Bagdad, Iraq from December 2021 to February 2022. This study was allowed and approved by the Scientific Jury and Editorial Board in the College of Medicine, Al-Mustansiriya University, according to reference No. 384WTR on 23/4/2021.

Animals

Twenty-eight Swiss-Albino male mice weighing 200–500 g were obtained from the animal house of the Iraqi Medical Research Center, Bagdad, Iraq. All experimental mice were kept in sterilized cages (3 per cage) under a 12/12 h light–dark cycle with standard atmospheric conditions. All mice had free access to water and food, and added libitum. To ensure adaptation, all rats were permitted to stay in their cages for 1 week.

Induction of DXR-induced cardiotoxicity

In this experimental study, each mouse was anesthetized with isoflurane at 2 mg/kg, and then DXR at 20 mg/kg was injected intraperitoneally (IP) using 26G sterile syringes. The mice were observed prudently for any deterioration in their general health. This method was performed according to the Al-Kuraishy and Al-Gareeb (2016).

Study design

Twenty-eight mice were allocated into four groups: negative control, did not receive any agents (n = 7); DXR group, received a single dose of DXR 20 mg/kg (n = 7); treated group A, pretreated with IVN 5 mg/kg orally for 10 days plus DXR 20 mg/kg on the 8th day (n = 7); treated group B, pretreated with IVN 10 mg/kg orally for 10 days plus DXR 20 mg/kg on the 8th day (n = 7). The duration of the study was 10 days. Each experiment was performed according to the Guidelines for Use and Care of Laboratory Animals.

Biochemical variables

At the end of the study, the mice were sacrificed under general anesthesia, and blood samples were drained from the heart chambers. The blood samples were directly centrifuged at 3000 rpm. The sera were stored at −20 °C in a special refrigerator until the time of analysis.

Inflammatory biomarkers, including tumor necrosis factor alpha (TNF-α), were assessed by ELISA kit methods (MyBioSource, San Diego, USA). In addition, serum lactate dehydrogenase (LDH), malondialdehyde (MDA), and cardiac troponin (cTn-I) levels were measured by the ELISA kit method (MyBioSource, San Diego, USA). Procedures for ELISA kits were performed according to the manufacturer’s protocol and instructions. All drugs and reagents were purchased from a private pharmaceutical company. Procedures for ELISA kits were performed according to the manufacturer’s protocol and instructions. All drugs and reagents were purchased from a private pharmaceutical company.

Data analysis was performed using SPSS (Statistics for Windows version 24.00, 2018, Armonk, NY, IBM Corp, USA). The presented data were expressed as a mean ± standard deviation. An unpaired t test and one-way analysis of variance were applied to detect differences among unrelated groups. The level of significance was applied when P < 0.05.
**Results**

TNF-α serum level was higher in DXR-treated mice (350.85 ± 12.82 ng/mL) compared to the control (44.91 ± 6.07 ng/mL), \( P < 0.0001 \). TNF-α serum level was reduced in both doses of IVN 5 mg/kg and 10 mg/kg to 139.99 ± 10.93 ng/mL and 135.94 ± 10.79 ng/mL, respectively, compared to DXR-treated mice \( P < 0.0001 \). However, IVN 5 mg/kg had an insignificant effect in reducing TNF-α serum level compared to IVN 10 mg/kg \( P = 0.24 \) (Fig. 1).

Cardiac troponin (cTn-I) level was higher in DXR-treated mice (148.24 ± 8.82 pg/mL) compared to the control (49.64 ± 8.08 ng/mL, \( P < 0.0001 \)). In addition, cTn-I serum level was reduced in both doses of IVN 5 mg/kg and 10 mg/kg to 83.96 ± 10.95 pg/mL and 75.14 ± 7.80 pg/mL, respectively, compared to DXR-treated mice \( P < 0.0001 \). However, the effect of reducing cTn-I was significant with IVN 10 mg/kg compared to IVN 5 mg/kg \( P = 0.03 \) (Fig. 2).

MDA serum level was higher in DXR-treated mice (1.91 ± 0.12 ng/mL) compared to the control (1.15 ± 0.20 ng/mL, \( P = 0.01 \)). MDA serum level was reduced in both doses of IVN 5 mg/kg and 10 mg/kg to 1.67 ± 0.10 ng/mL and 1.30 ± 0.11 ng/mL, respectively, compared to DXR-treated mice \( P < 0.01 \). Though, IVN 10 mg/kg had a significant effect in reducing MDA serum level compared to IVN 5 mg/kg \( P = 0.04 \) (Fig. 3).

Finally, LDH serum level was higher in DXR-treated mice (17.53 ± 4.05 IU/L) compared to the control (7.95 ± 2.80 IU/L, \( P = 0.01 \)). LDH serum level was reduced in both doses of IVN 5 mg/kg and 10 mg/kg to 14.75 ± 3.67 IU/L and 13.29 ± 3.33 IU/L, respectively, compared to DXR-treated mice \( P < 0.01 \). Nevertheless, the effect of reducing LDH serum level was insignificant to mice treated with IVN 5 mg/kg compared to mice treated with IVN10mg/kg \( P = 0.09 \) (Fig. 4).

**Discussion**

Previous studies have reported that anthracycline-induced cardiotoxicity is approximately 9, and 98% of these cases tend to develop within 1 year. DOX and other anthracycline-induced cardiotoxicities are irreversible in most cases, and 2-year survival has been shown to be 50% when heart failure is caused by anthracycline (Felker et al. 2000). Treatment of DOX-induced cardiotoxicity and associated heart failure is difficult due to the development of resistance to the inotropes (Felker et al. 2000). IVN improves cardiac hemodynamic dysfunction induced by DOX through an increase in stroke volume (Chiu et al. 2019). IVN promotes coronary perfusion and increases left ventricular diastolic filling and cardiac contractility. The positive inotropic effect of IVN is mediated by sarcoplasmic and endoplasmic ATPase activity with a noteworthy reduction of afterload (Yang et al. 2020).

The current study found that IVN had a significant dose-dependent effect in reducing DXR-induced cardiotoxicity. Colak et al. found that IVN had a protective effect against DXR-induced cardiotoxicity in rats (Colak et al. 2012). More specifically, the authors found that IVN-improved
electrocardiographic records and blood pressure alteration in rats with experimental DXR-induced cardiotoxicity (Colak et al. 2012). Besides, it has been suggested that IVN attenuates left ventricular and autonomic dysfunction in DXR-induced cardiotoxicity in rats (El-Naggar et al. 2018). Altogether, these findings underline the protective effect of IVN against DXR-induced cardiotoxicity, which is also confirmed in the present study.

The underlying mechanism of the cardioprotective effect of IVN might be linked to its anti-inflammatory and antioxidant effects (Wang et al. 2022). In the present study, IVN reduced TNF-α, cTn-I, MDA, and LDH serum levels compared to the DXR-induced group. A meta-analysis of randomized trials investigating the effect of IVN on atrial fibrillation illustrated that IVN was effective in the management of atrial fibrillation due to its anti-inflammatory and antioxidant effects (Wang et al. 2022). A previous pilot study by Dominguez-Rodriguez and coworkers demonstrated that IVN had a latent role in decreasing acute coronary syndrome through inhibition of pro-inflammatory cytokines release, including TNF-α (Dominguez-Rodriguez et al. 2012). Likewise, IVN inhibits the expression of inflammatory signaling pathways, such as p38 mitogen activated protein kinase (p39MAPK), in rats with experimental DXR-induced cardiotoxicity (Zuo et al. 2019). Furthermore, a recent study showed that IVN attenuates kindling in rats through its antioxidant effects (Ahmed et al. 2020). Of note, exaggeration of inflammatory reactions and oxidative stress may induce the development of heart failure (Onohuean et al. 2021; Teibo et al. 2021). These findings suggest that the anti-inflammatory and antioxidant properties of IVN could be a potential mechanism in reducing DXR-induced cardiotoxicity.

Nonetheless, one of the most intriguing findings of the current study was the dose-dependent effect of IVN in reducing cTn-I and MDA serum levels in rats with DXR-induced cardiotoxicity. Our results highlight the effectiveness of IVN in decreasing DXR-induced cardiotoxicity through inhibition of lipid peroxidation and cardiomyocyte injury. Boshra et al. illustrated that IVN could mitigate cardiomyocyte injury by inhibiting the apoptosis and generation of ROS, which has been known to trigger the development of lipid peroxidation in mice with DXR-induced cardiotoxicity (Boshra and Shalaby 2015). In virtue of its anti-inflammatory and antioxidant properties, IVN could be a potential candidate in the mitigation of DXR-induced cardiotoxicity.

In its clinical perspective, IVN might be a pioneer drug in attenuating cardiotoxicity, mainly in patients with heart failure, arrhythmias, and malignancies treated by DXR. It has been shown that unlike β-blockers, IVN does not decrease ventricular force (Su et al. 2020; Al-Kuraishy et al. 2021b, 2022c, d; Lawal et al. 2021) and can also reduce COVID-19-induced cardiovascular complications due to its anti-inflammatory and antioxidant properties (Al-Kuraishy et al. 2021c, 2022e; Batiha et al. 2021, 2022). In addition, IVN facilitates a pleiotropic cardioprotective effect against isoproterenol-induced acute cardiac injury by increasing the ventricular fibrillation threshold (Simko et al. 2021).

A clinical trial conducted by Izco et al. showed that acute heart failure patients could benefit from heart rate reduction, as myocardial consumption and oxidative stress are related to tachycardia. IVN could have a clinical role in attenuating catecholamine-induced tachycardia (Izco et al. 2020). Combined with trimetazidine, IVN reduces the risk of acute cardiac injury in patients undergoing percutaneous coronary intervention as a result of an anti-ischemic effect mediated by a decrease in myocardial oxygen consumption (Chen 2021). It has been shown that IVN induces the release of protective microvesicles from endothelial cells, which promote cell proliferation and reduce cardiac necrosis following ischemic reperfusion injury (Ramirez-Carracedo et al. 2020). IVN promotes expression of extracellular matrix metalloproteinase is induced, which prevents the development of myocardial necrosis (Ramirez-Carracedo et al. 2020).

Thus, IVN can be used as a prophylactic agent to prevent the development of acute cardiac injury as shown in DXR-induced cardiotoxicity.

Consequently, IVN could be effective in treating patients with heart failure and arrhythmias during DXR chemotherapy.

**Conclusion**

The anti-inflammatory and antioxidant effects of IVN render this drug an effective agent in mitigating and preventing DXR-induced cardiotoxicity. Remarkably, this study revealed the dose-dependent effect of IVN on the attenuation of DXR-induced cardiotoxicity due to the inhibition of lipid peroxidation and cardiomyocyte injury. In this state, large-scale experimental, preclinical, and clinical studies are warranted to validate our experimental findings.
The role of ivabradine in doxorubicin-induced cardiotoxicity: exploring of underlying... 2445

Author contributions Conceptualization: HMA, HKI, and AIA-G. Data curation: HMA, HKI, and AIA-G. Formal analysis: HMA, AIA, HKI, MME, and GEB. Methodology: HMA, HKI, and AIA. Investigation: MME, GEB, and AY. Visualization: HMA, AIA, HKI, MME, ASA, HAK, and GEB. Writing—original draft: HMA, HKI, MME, GEB, and AIA. Writing—review & editing: HMA, HKI, AIA, MME, AY, ASA, HAK, and GEB. All authors have read and agreed to the published version of the manuscript.

Funding The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.

Availability of data and materials All data generated or analyzed during this study are included in this published article.

Declarations

Conflict of interests The authors have no relevant financial or non-financial interests to disclose.

Ethics approval This study was performed in the College of Medicine, Department of Clinical Pharmacology and Therapeutic, Al-Mustansiriyya University, Bagdad, Iraq from December 2021 to February 2022. This study was allowed and approved by the Scientific Jury and Editorial Board in the College of Medicine, Al-Mustansiriyah University according to the reference No. 384WTR in 23/4/2021.

Consent to participate Not applicable.

Consent to publish Not applicable.

References

Ahmed HS, Abdelsamee AA, Kamel EM (2020) Potential antiepileptic effect of ivabradine against Pentylenetetrazole-induced-kindling in male mice. Med J 26(3):483–492

Al-Kuraishy HM, Al-Gareeb AI (2016) Potential effects of pomegranate on lipid peroxidation and pro-inflammatory changes in daunorubicin-induced cardiotoxicity in rats. Int J Prev Med 7:85. https://doi.org/10.4103/2008-7802.184314

Al-Kuraishy HM, Al-Gareeb AI, Al-Hussainy HA, Al-Harcan NAH, Alexiou A, Batisha GE (2022a) Neutrophil extracellular traps (NETs) and Covid-19: a new frontiers for therapeutic modality. Int Immunopharmacol 104:108516. https://doi.org/10.1016/j.intimp.2021.108516

Al-Kuraishy HM, Al-Gareeb AI, Al-Niemi MS, Aljowawe RM, Almutairi SM, Alexiou A, Batisha GE (2022b) The prospective treatment effect of allopurinol on the oxidative stress index and endothelial dysfunction in Covid-19. Inflammation 45(4):1651–1667. https://doi.org/10.1007/s10753-022-01648-7

Al-Kuraishy HM, Al-Gareeb AI, Al-Qarni M, Cruz-Martins N, El-Saber Batisha G (2021a) Pleiotropic effects of tetracyclines in the management of COVID-19: emerging perspectives. Front Pharmacol 12:642822. https://doi.org/10.3389/fphar.2021.642822

Al-Kuraishy HM, Al-Gareeb AI, Buttanuri M, Batisha GE (2022c) The crucial role of prolactin-lactogenic hormone in Covid-19. Mol Cell Biochem 477(5):1381–1392. https://doi.org/10.1007/s10100-022-04381-9

Al-Kuraishy HM, Al-Gareeb AI, Fagayinbo MS, Batisha GE (2022d) Vinpocetine is the adjuvant agent in the management of COVID-19. Future Sci. https://doi.org/10.2144/fsoa-2021-0099

Al-Kuraishy HM, Al-Gareeb AI, Mostafa-Hedeb G, Kasozi KI, Zirintunda G, Aslam A et al (2021b) Effects of β-blockers on the sympathetic and cytokines storms in Covid-19. Front Immunol 12:749291. https://doi.org/10.3389/fimmu.2021.749291

Al-Kuraishy HM, Al-Gareeb AI, Qusti S, Alshammari EM, Gyebi GA, Batiha GE (2021c) Covid-19-Induced dysautonomia: amenace of sympathetic storm. ASN Neuro 13:17590914211057636. https://doi.org/10.1177/17590914211057636

Al-Kuraishy HM, Al-Gareeb AI, Welson NN, Batisha GE (2022c) Trimetazidine and COVID-19-induced acute cardiac injury: a missed key. Int J Clin Pharm 44(3):832–833. https://doi.org/10.1007/s11096-022-01408-5

Al-Kuraishy HM, Al-Gareeb AL, Najji HA (2019) Fexbuxostat modulates oxidative and apoptotic pathways in acute doxorubicin-induced cardiotoxicity: an experimental animal model study. Asian J Pharm Clin Res 12(4):73–76

Al-Kuraishy HM, Khaleel KJ, Mohammed MA (2015) Significant attenuation and amelioration effects of labetalol in doxorubicin-induced cardiotoxicity: an animal model study. Journal-CVS 3(2):25–29. https://doi.org/10.5455/jcvs.2015321

Batisha GE, Al-Gareeb AI, Qusti S, Alshammari EM, Kaushik D, Verma R, Al-Kuraishy HM (2022) Deciphering the immunobosstoning potential of macro and micronutrients in COVID support therapy. Environ Sci Pollut Res Int 29(29):43516–43531. https://doi.org/10.1007/s11365-022-00757-5

Batisha GES, Gari A, Elshony N, Shaheen AM, Abubakar MB, Adeyemi SB, Al-Kuraishy HM (2021) Hypertension and its management in COVID-19 patients: the assorted view. Int J Cardiol Cardiovasc Risk Prev 11:200121. https://doi.org/10.1016/j.jcjr.2021.200121

Boshr V, Shalaby A (2015) Impact of ivabradine on reactive nitrogen and oxygen radicals in doxorubicin induced acute cardio toxicity in mice. Br J MedResDev 6(12):1166–1176. https://doi.org/10.9734/BJMMR/2015/10764

Chen C (2021) Protection of ivabradine combined with trimetazidine on myocardial injury after percutaneous coronary intervention in patients with coronary artery disease evaluated by magnetic resonance image under convolutional neural network. Contrast Media Mol Imaging 2021:3150938. https://doi.org/10.1155/2021/3150938

Chiu MH, Howlett JG, Sharma NC (2019) Initiation of ivabradine in cardiogenic shock. ESC Heart Fail 6(5):1088–1091. https://doi.org/10.1002/ehf2.12499

Colak MC, Parlakpinar HA, Tasdemir S, Samdanci E, Kose E, Polat A et al (2012) Therapeutic effects of ivabradine on hemodynamic parameters and cardiotoxicity induced by doxorubicin treatment in rat. Hum Exp Toxicol 31(9):945–954. https://doi.org/10.1177/0960377012438288

Domínguez-Rodriguez A, Consuegra-Sanchez L, Blanco-Palacios G, Abreu-Gonzalez P, Sanchez-Grande A, Bosa-Ojeda F, Kaski JC (2012) Anti-inflammatory effects of ivabradine in patients with acute coronary syndrome: a pilot study. Int J Cardiol 158(1):160–162. https://doi.org/10.1016/j.ijcard.2012.04.076

El-Naggar AE, El-Gowilly SM, Sharabi FM (2018) Possible ameliorative effect of ivabradine on the autonomic and left ventricular dysfunction induced by doxorubicin in male rats. J Cardiovasc Pharmacol 72(1):22–31. https://doi.org/10.1097/FJC.0000000000000586

Felker GM, Thompson RE, Hare JM, Hruban RH, Clemeton DE, Howard DL et al (2000) Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 342(15):1077–1084. https://doi.org/10.1056/NEJM20004133421502

Izco MP, Ramírez-Carracedo R, Hernández Navarro I, Osorio Ruiz A, CASTEJÓN NAVARRO B, CUADRADO BERRCAL I et al (2020) Ivabradine in acute heart failure: effects on heart rate and hemodynamic parameters in a randomized and controlled swine trial. Cardiol J 27(1):62–71. https://doi.org/10.5603/CJ.a2018.0078
Jasim ST, Al-Kuraishy HM, Al-Gareeb AI (2019) Gingko Biloba protects cardiomyocytes against acute doxorubicin induced cardiotoxicity by suppressing oxidative stress. JPMMA 69(8):S103–S107.
Koka S, Das A, Zhu SG, Durrant D, Xi L, Kukreja RC (2010) Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect. J Pharmacol Exp Ther 334(3):1023–1030. https://doi.org/10.1124/jpet.110.170191
Kumari H, Huang WH, Chan MWY (2020) Review on the role of epigenetic modifications in doxorubicin-induced cardiotoxicity. Front Cardiovasc Med 7:56. https://doi.org/10.3389/fcvm.2020.00056
Lawal B, Tseng SH, Olugbodi JO, Iamsaard S, Ilesanmi OB, Mahmoud MH et al (2021) Pan-cancer analysis of immune complement signature C3/C5/C3AR1/C5AR1 in association with tumor immune evasion and therapy resistance. Cancers 13(16):4124. https://doi.org/10.3390/cancers13164124
Onohuean H, Al-Kuraishy HM, Al-Gareeb AI, Qusti S, Alshammari EM, Batia GE (2021) Covid-19 and development of heart failure: mystery and truth. Naunyn Schmiedebergs Arch Pharmacol 394(10):2013–2021. https://doi.org/10.1007/s00210-021-02147-6
Ramirez-Carracedo R, Tesoro L, Hernandez I, Diez-Mata J, Botana L, Saura M et al (2020) Ivabradine-stimulated microvesicle release induces cardiac protection against acute myocardial infarction. Int J Mol Sci 21(18):6566. https://doi.org/10.3390/ijms21186566
Shah MA, Rasul A, Yousaf R, Haris M, Faheem HI, Hamid A et al (2021) Combination of natural antivirals and potent immune invigators: a natural remedy to combat COVID-19. Phytother Res 35(12):6530–6551. https://doi.org/10.1002/ptr.7228
Simko F, Baka T, Repova K, Aziriova S, Krajičirovićova K, Paulis L, Adamcová M (2021) Ivabradine improves survival and attenuates cardiac remodeling in isoproterenol-induced myocardial injury. Fundam Clin Pharmacol 35(4):744–748. https://doi.org/10.1111/fcp.12620
Sindhu RK, Verma R, Salgotra T, Rahman MH, Shah M, Akter R et al (2021) Impacting the remedial potential of Nanodelivery-based flavonoids for breast cancer treatment. Molecules 26(17):5163. https://doi.org/10.3390/molecules26175163
Su Y, Ma T, Wang Z, Dong B, Tai C, Wang H et al (2020) Efficacy of early initiation of ivabradine treatment in patients with acute heart failure: rationale and design of SHIFT-AHF trial. ESC Heart Fail 7(6):4465–4471. https://doi.org/10.1002/ehf2.12997
Teibo JO, Ayinde KS, Olaoba OT, Adelusi TI, Teibo TKA, Bamikunle MV et al (2021) Functional foods’ bioactive components and their chemoprevention mechanism in cervical, breast, and liver cancers: a systematic review. Funct Foods Health Dis 11(11):559–585. https://doi.org/10.31989/ffhd.v11i11.818
Wang Z, Wang W, Li H, Zhang A, Han Y, Wang J, Hou Y (2022) Ivabradine and atrial fibrillation: a meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol 79(4):549–557. https://doi.org/10.1097/FJC.0000000000001209
Xu H, Yu W, Sun S, Li C, Zhang Y, Ren J (2020) Luteolin attenuates doxorubicin-induced cardiotoxicity through promoting mitochondrial autophagy. Front Physiol 11:113. https://doi.org/10.3389/fphys.2020.00113
Yang M, Chen L, Hua T, Zou Y, Yang Z (2020) Beneficial effects of ivabradine on post-resuscitation myocardial dysfunction in a porcine model of cardiac arrest. Shock 53(5):630–636. https://doi.org/10.1097/SHK.0000000000001403
Zuo G, Ren X, Qian X, Ye P, Luo J, Gao X et al (2019) Inhibition of JNK and p38MAPK-mediated inflammation and apoptosis by ivabradine improves cardiac function in streptozotocin-induced diabetic cardiomyopathy. J Cell Physiol 234(2):1925–1936. https://doi.org/10.1002/jcp.27070

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.